https://www.selleckchem.com/pe....ptide/angiotensin-ii
6%), cirrhosis (n=1,151; 22.9%), HCV RNA 6×106 IU/mL (n=866; 17.2%), or liver stiffness 9.6 kPa (n=1,721; 34.2%) (100.0%, 99.3%, 99.4%, and 99.4%, respectively). No severe adverse events (AEs) were reported, and there was no dose reduction or interruption due to AE. The most common AEs were headache (n=472; 9.4%), fatigue (n=306; 6.2%), abdominal discomfort (n=295; 5.9%), and skin rash (n=141; 2.8%). LDV/SOF showed high efficacy and safety for patients with genotype 1, especially 1b HCV, in Mongolia. The real
Like
Comment
Share
